{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The linear regression model will used to investigate the correlation between MR imaging and peritumoral BBB disruption. To account for correlation among the repeated measures from the same patient, the longitudinal data will be analyzed with the use of linear generalized estimating equation (GEE). Whether the average measurements differ at the multiple time points will be evaluated through GEE model. Least-square means at each time points will be presented and standard errors will be calculated within the use of the GEE sandwich method when accounting for within-patient correlation.","groups":[{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * Every 12 weeks (+/- 7 days) for the first year or until disease progression","id":"OG000","title":"Arm A (MRI-guided Laser Ablation)"},{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m\\^2 over 5-30 minutes\n* Following the completion of doxorubin, etoposide 50 mg/m\\^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first","id":"OG001","title":"Arm B (MRI-guided Laser Ablation, Doxorubicin, Etoposide)"}],"populationDescription":"Data was not collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"1 year from MLA","title":"Correlation of MR Imaging With Peritumoral BBB Disruption","type":"SECONDARY"}